Abstract
The role of the renin-angiotensin system (RAS) in the development of various malignancies has recently been extensively examined and, since it has been shown to significantly influence many aspect of cancer initiation and progression, the idea of RAS-targeted anticancer therapy has arisen. This article reviews the mechanisms underlying RAS-induced physiological and pathological responses related to cancer biology, including tumor growth, cell proliferation, apoptosis, angiogenesis, inflammation, and protein degradation, emphasizing the associated cellular transduction schemes activated by main RAS effectors. Also the dual nature of RAS-dependent effects, resulting from its complex physiology has been commented. Finally, based on the available data from clinical trials and experimental studies, the possibilities of the introduction of RAS-modulating drugs into standard clinical practice in oncology have been discussed with the focus on both, positive and negative effects associated with the administration of various classes of pharmaceuticals to cancer patients.
Keywords: The renin-angiotensin system, cancer therapy, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, transduction mechanisms.
Current Pharmaceutical Design
Title:The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Volume: 19 Issue: 40
Author(s): Katarzyna Regulska, Beata Stanisz and Milosz Regulski
Affiliation:
Keywords: The renin-angiotensin system, cancer therapy, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, transduction mechanisms.
Abstract: The role of the renin-angiotensin system (RAS) in the development of various malignancies has recently been extensively examined and, since it has been shown to significantly influence many aspect of cancer initiation and progression, the idea of RAS-targeted anticancer therapy has arisen. This article reviews the mechanisms underlying RAS-induced physiological and pathological responses related to cancer biology, including tumor growth, cell proliferation, apoptosis, angiogenesis, inflammation, and protein degradation, emphasizing the associated cellular transduction schemes activated by main RAS effectors. Also the dual nature of RAS-dependent effects, resulting from its complex physiology has been commented. Finally, based on the available data from clinical trials and experimental studies, the possibilities of the introduction of RAS-modulating drugs into standard clinical practice in oncology have been discussed with the focus on both, positive and negative effects associated with the administration of various classes of pharmaceuticals to cancer patients.
Export Options
About this article
Cite this article as:
Regulska Katarzyna, Stanisz Beata and Regulski Milosz, The Renin-angiotensin System as a Target of Novel Anticancer Therapy, Current Pharmaceutical Design 2013; 19 (40) . https://dx.doi.org/10.2174/13816128113199990508
DOI https://dx.doi.org/10.2174/13816128113199990508 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of Insulins
Current Drug Safety Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Rewiring the Heart: Stem Cell Therapy to Restore Normal Cardiac Excitability and Conduction
Current Stem Cell Research & Therapy Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Recent Advances in the Development of Thioredoxin Reductase Inhibitors as Anticancer Agents
Current Drug Targets The Pim Kinases: New Targets for Drug Development
Current Drug Targets Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer’s Disease Therapy: Advances in Chemical and Biological Research
Current Medicinal Chemistry Nanotechnology Platforms; An Innovative Approach to Brain Tumor Therapy
Medicinal Chemistry Anti-cancer Effects of Curcumin on Head and Neck Cancers
Anti-Cancer Agents in Medicinal Chemistry The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Current Rheumatology Reviews Surgical Complications of Hyperglycaemia
Current Diabetes Reviews Potential Application of 5-Aryl-Substituted 2-Aminobenzamide Type of HDAC1/2- Selective Inhibitors to Pharmaceuticals
Current Pharmaceutical Design Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics The Trigeminocardiac Reflex as Oxygen Conserving Reflex in Humans: Its Ischemic Tolerance Potential
Vascular Disease Prevention (Discontinued) Patent Selections:
Recent Patents on Regenerative Medicine